GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$42.87 USD
-0.12 (-0.28%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $42.86 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Price, Consensus and EPS Surprise
GSK 42.87 -0.12(-0.28%)
Will GSK be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
GSK PLC Sponsored ADR (GSK) is Attracting Investor Attention: Here is What You Should Know
Here's Why GSK (GSK) Gained But Lagged the Market Today
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
GSK (GSK) Stock Moves -0.09%: What You Should Know
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
Other News for GSK
UK dividends calendar
Interesting GSK Put And Call Options For May 10th
WuXi Biologics Reports Solid 2023 Annual Results
GSK Executive Sells Shares on LSE
Peering Into GSK's Recent Short Interest